Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Pursuing precision medicine in a flagship lung cancer trial July 15, 2020 Coping with COVID: New Stimulus Funds and Unemployment Benefit Update January 5, 2021 Time to get stratified January 10, 2023 £82,000 of Donations Pour in for Mom with Incurable Cancer to... April 10, 2019 Load more HOT NEWS Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... Helping Kids Cope With Cancer: “Your Stories” Podcast Predicting future breast cancer with precision Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT...
